
    
      296 patients have been randomized 1:1 between the experimental arm (Arm A: approximately 125
      patients treated with palbociclib plus exemestane) and the control arm (Arm B: approximately
      125 patients treated with capecitabine) before the approval of this protocol version (Cohort
      1).

      Approximately 300 patients will be randomized 1:1 between the experimental arm (Arm A:
      approximately 150 patients treated with palbociclib plus fulvestrant) and the control arm
      (Arm B: approximately 150 patients treated with capecitabine) from the approval of this
      protocol version (Cohort 2).
    
  